Continue to site >
Trending ETFs

Name

As of 03/27/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$75.28

$5.23 B

0.15%

$0.11

0.77%

Vitals

YTD Return

8.7%

1 yr return

20.6%

3 Yr Avg Return

7.8%

5 Yr Avg Return

11.8%

Net Assets

$5.23 B

Holdings in Top 10

35.5%

52 WEEK LOW AND HIGH

$74.5
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 0.77%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 32.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$1,000,000

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 03/27/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$75.28

$5.23 B

0.15%

$0.11

0.77%

JFNIX - Profile

Distributions

  • YTD Total Return 8.7%
  • 3 Yr Annualized Total Return 7.8%
  • 5 Yr Annualized Total Return 11.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.32%
DIVIDENDS
  • Dividend Yield 0.2%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Janus Henderson Global Life Sciences Fund
  • Fund Family Name
    Janus Henderson Funds
  • Inception Date
    Dec 31, 1998
  • Shares Outstanding
    N/A
  • Share Class
    I
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Andrew Acker

Fund Description

The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Fund’s pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the “life sciences” sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. So, for example, companies with a “life science orientation” include companies engaged in research, development, production, or distribution of products or services related to health and personal care, medicine, or pharmaceuticals. The Fund implements its investment policies by investing primarily in equity securities of U.S. and foreign companies selected for their growth potential. The Fund normally invests in issuers from several different countries, which may include the United States. An issuer is deemed to be economically tied to a country or countries if one or more of the following tests are met: (i) the issuer is organized in, or its primary business office or principal trading market of its equity is located in, the country; (ii) a majority of the issuer’s revenues are derived from one or more countries; or (iii) a majority of the issuer’s assets are located in one or more countries. The Fund may, under unusual circumstances, invest in a single country. The Fund may invest in shares of companies through initial public offerings and private placements.Portfolio management applies a “bottom up” approach in choosing investments. In other words, portfolio management looks at companies one at a time to determine if a company is an attractive investment opportunity and if it is consistent with the Fund’s investment policies. In conducting the “bottom up” analysis, portfolio management considers factors including a company’s growth potential, the strength of a company’s management, and a company’s sustainable competitive advantages, returns on investment capital, and cash flow generation. Portfolio management also applies screens, which incorporate third-party inputs, to (i) seek to avoid investing in issuers that are United Nations Global Compact violators and (ii) seek to invest at least 80% of the Fund’s net assets, under normal circumstances, in issuers with an MSCI (or an equivalent third-party data provider, as determined by portfolio management) ESG rating of BB or higher.The Fund will generally consider selling a stock when, in portfolio management’s opinion, the stock shows declining fundamentals, its competitive advantages have deteriorated, or if the stock reaches its targeted value. The Fund will also consider selling a stock if, in portfolio management’s opinion, a superior investment opportunity arises.The Fund may seek to earn additional income through lending its securities to certain qualified broker-dealers and institutions on a short-term or long-term basis, in an amount equal to up to one-third of its total assets as determined at the time of the loan origination.
Read More

JFNIX - Performance

Return Ranking - Trailing

Period JFNIX Return Category Return Low Category Return High Rank in Category (%)
YTD 8.7% -13.0% 22.1% 30.67%
1 Yr 20.6% -19.6% 37.7% 25.15%
3 Yr 7.8%* -30.2% 13.9% 14.10%
5 Yr 11.8%* -2.8% 14.5% 9.56%
10 Yr 11.9%* 0.3% 14.3% 3.74%

* Annualized

Return Ranking - Calendar

Period JFNIX Return Category Return Low Category Return High Rank in Category (%)
2023 2.9% -12.6% 19.0% 53.37%
2022 -2.9% -53.9% 3.2% 5.13%
2021 -3.0% -39.6% 24.2% 62.18%
2020 16.4% -13.6% 178.2% 37.09%
2019 21.5% 3.8% 63.8% 43.70%

Total Return Ranking - Trailing

Period JFNIX Return Category Return Low Category Return High Rank in Category (%)
YTD 8.7% -13.0% 22.1% 30.67%
1 Yr 20.6% -19.6% 37.7% 25.15%
3 Yr 7.8%* -30.2% 13.9% 14.10%
5 Yr 11.8%* -2.8% 14.5% 9.56%
10 Yr 11.9%* 0.3% 14.3% 3.74%

* Annualized

Total Return Ranking - Calendar

Period JFNIX Return Category Return Low Category Return High Rank in Category (%)
2023 7.5% -12.6% 19.0% 23.93%
2022 -2.6% -53.9% 3.7% 13.46%
2021 6.9% -33.9% 26.0% 60.26%
2020 25.6% -0.7% 180.6% 39.07%
2019 29.3% 4.6% 63.8% 34.07%

NAV & Total Return History


JFNIX - Holdings

Concentration Analysis

JFNIX Category Low Category High JFNIX % Rank
Net Assets 5.23 B 6.16 M 45 B 15.95%
Number of Holdings 122 23 413 15.34%
Net Assets in Top 10 1.74 B 2.07 M 20.4 B 16.56%
Weighting of Top 10 35.48% 18.1% 77.0% 85.89%

Top 10 Holdings

  1. UnitedHealth Group Inc 6.47%
  2. Eli Lilly Co 5.13%
  3. Novo Nordisk A/S - Class B 4.20%
  4. AstraZeneca PLC 3.95%
  5. Merck Co Inc 3.13%
  6. Abbott Laboratories 2.66%
  7. Sanofi 2.65%
  8. AbbVie Inc 2.61%
  9. Vertex Pharmaceuticals Inc 2.36%
  10. Novartis AG (ADR) 2.33%

Asset Allocation

Weighting Return Low Return High JFNIX % Rank
Stocks
91.07% 87.17% 106.13% 92.02%
Preferred Stocks
1.38% 0.00% 7.86% 12.88%
Convertible Bonds
0.13% 0.00% 0.37% 5.06%
Cash
0.03% 0.00% 32.99% 93.25%
Bonds
0.02% 0.00% 12.39% 10.43%
Other
0.00% -22.99% 17.73% 50.92%

Stock Sector Breakdown

Weighting Return Low Return High JFNIX % Rank
Healthcare
100.00% 59.26% 100.00% 17.09%
Utilities
0.00% 0.00% 0.00% 23.42%
Technology
0.00% 0.00% 22.69% 29.11%
Real Estate
0.00% 0.00% 5.89% 27.22%
Industrials
0.00% 0.00% 7.02% 28.48%
Financial Services
0.00% 0.00% 1.60% 46.84%
Energy
0.00% 0.00% 0.00% 23.42%
Communication Services
0.00% 0.00% 9.11% 26.58%
Consumer Defense
0.00% 0.00% 25.73% 32.91%
Consumer Cyclical
0.00% 0.00% 1.92% 28.48%
Basic Materials
0.00% 0.00% 7.16% 51.90%

Stock Geographic Breakdown

Weighting Return Low Return High JFNIX % Rank
US
76.76% 66.21% 104.41% 85.28%
Non US
14.31% 0.00% 29.78% 22.70%

Bond Sector Breakdown

Weighting Return Low Return High JFNIX % Rank
Corporate
13.28% 0.00% 83.51% 15.49%
Cash & Equivalents
0.03% 0.00% 100.00% 79.14%
Derivative
0.00% -0.03% 17.73% 38.04%
Securitized
0.00% 0.00% 0.00% 20.42%
Municipal
0.00% 0.00% 1.73% 21.13%
Government
0.00% 0.00% 29.44% 21.83%

Bond Geographic Breakdown

Weighting Return Low Return High JFNIX % Rank
US
0.02% 0.00% 11.75% 10.43%
Non US
0.00% 0.00% 3.33% 24.54%

JFNIX - Expenses

Operational Fees

JFNIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.77% 0.08% 4.28% 71.17%
Management Fee 0.64% 0.03% 1.25% 39.88%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% 50.00%

Sales Fees

JFNIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

JFNIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% 24.39%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JFNIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 32.00% 0.00% 238.00% 28.26%

JFNIX - Distributions

Dividend Yield Analysis

JFNIX Category Low Category High JFNIX % Rank
Dividend Yield 0.15% 0.00% 6.97% 7.98%

Dividend Distribution Analysis

JFNIX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annually Annual Annual

Net Income Ratio Analysis

JFNIX Category Low Category High JFNIX % Rank
Net Income Ratio 0.32% -2.54% 1.85% 17.95%

Capital Gain Distribution Analysis

JFNIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Distributions History

View More +

JFNIX - Fund Manager Analysis

Managers

Andrew Acker


Start Date

Tenure

Tenure Rank

May 01, 2007

15.09

15.1%

"Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience."

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.84 0.25